Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.29
NAS:WMGI's Cash-to-Debt is ranked lower than
84% of the 325 Companies
in the Global Medical Devices industry.

( Industry Median: 2.55 vs. NAS:WMGI: 0.29 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:WMGI' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.18  Med: 0.7 Max: N/A
Current: 0.29
Equity-to-Asset 0.27
NAS:WMGI's Equity-to-Asset is ranked lower than
86% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. NAS:WMGI: 0.27 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:WMGI' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.27  Med: 0.7 Max: 0.79
Current: 0.27
0.27
0.79
Piotroski F-Score: 5
Altman Z-Score: 0.43
Beneish M-Score: -3.65
WACC vs ROIC
7.82%
-7.35%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -14.59
NAS:WMGI's Operating Margin % is ranked lower than
66% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 2.62 vs. NAS:WMGI: -14.59 )
Ranked among companies with meaningful Operating Margin % only.
NAS:WMGI' s Operating Margin % Range Over the Past 10 Years
Min: -116.46  Med: -16.1 Max: -2.74
Current: -14.59
-116.46
-2.74
Net Margin % -63.45
NAS:WMGI's Net Margin % is ranked lower than
73% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 1.55 vs. NAS:WMGI: -63.45 )
Ranked among companies with meaningful Net Margin % only.
NAS:WMGI' s Net Margin % Range Over the Past 10 Years
Min: -113.05  Med: -27.11 Max: -7.84
Current: -63.45
-113.05
-7.84
ROE % -56.06
NAS:WMGI's ROE % is ranked lower than
78% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 1.31 vs. NAS:WMGI: -56.06 )
Ranked among companies with meaningful ROE % only.
NAS:WMGI' s ROE % Range Over the Past 10 Years
Min: -64.55  Med: -24.23 Max: -5.19
Current: -56.06
-64.55
-5.19
ROA % -19.68
NAS:WMGI's ROA % is ranked lower than
67% of the 327 Companies
in the Global Medical Devices industry.

( Industry Median: 0.06 vs. NAS:WMGI: -19.68 )
Ranked among companies with meaningful ROA % only.
NAS:WMGI' s ROA % Range Over the Past 10 Years
Min: -40.3  Med: -10.97 Max: -3.73
Current: -19.68
-40.3
-3.73
ROC (Joel Greenblatt) % -36.16
NAS:WMGI's ROC (Joel Greenblatt) % is ranked lower than
62% of the 323 Companies
in the Global Medical Devices industry.

( Industry Median: 4.26 vs. NAS:WMGI: -36.16 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:WMGI' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -197.56  Med: -35.23 Max: -18
Current: -36.16
-197.56
-18
3-Year Revenue Growth Rate 10.00
NAS:WMGI's 3-Year Revenue Growth Rate is ranked higher than
69% of the 237 Companies
in the Global Medical Devices industry.

( Industry Median: 4.40 vs. NAS:WMGI: 10.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:WMGI' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -14.9  Med: -4.3 Max: 10
Current: 10
-14.9
10
3-Year EBITDA Growth Rate -58.80
NAS:WMGI's 3-Year EBITDA Growth Rate is ranked lower than
96% of the 208 Companies
in the Global Medical Devices industry.

( Industry Median: 5.10 vs. NAS:WMGI: -58.80 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:WMGI' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -58.8  Med: -11.9 Max: 101.8
Current: -58.8
-58.8
101.8
3-Year EPS without NRI Growth Rate -35.00
NAS:WMGI's 3-Year EPS without NRI Growth Rate is ranked lower than
83% of the 203 Companies
in the Global Medical Devices industry.

( Industry Median: 1.40 vs. NAS:WMGI: -35.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:WMGI' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -38.1  Med: 20.2 Max: 89.2
Current: -35
-38.1
89.2
» NAS:WMGI's 30-Y Financials

Financials (Next Earnings Date: 2017-08-03 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

WMGI Guru Trades in Q2 2016

Ken Fisher 2,445,110 sh (+4.95%)
Mario Gabelli 217,519 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund Sold Out
Keeley Asset Management Corp 1,524,987 sh (-0.76%)
Steven Cohen 1,771,700 sh (-2.44%)
Jim Simons 136,111 sh (-59.06%)
» More
Q3 2016

WMGI Guru Trades in Q3 2016

Joel Greenblatt 28,955 sh (New)
Eaton Vance Worldwide Health Sciences Fund 1,009,222 sh (New)
Ken Fisher 2,593,555 sh (+6.07%)
Mario Gabelli 217,519 sh (unchged)
Keeley Asset Management Corp 1,318,524 sh (-13.54%)
Jim Simons 115,207 sh (-15.36%)
Steven Cohen 906,700 sh (-48.82%)
» More
Q4 2016

WMGI Guru Trades in Q4 2016

Mario Gabelli 217,519 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 1,009,222 sh (unchged)
Joel Greenblatt Sold Out
Jim Simons Sold Out
Ken Fisher 2,503,745 sh (-3.46%)
Keeley Asset Management Corp 1,199,691 sh (-9.01%)
Steven Cohen 127,300 sh (-85.96%)
» More
Q1 2017

WMGI Guru Trades in Q1 2017

Joel Greenblatt 14,815 sh (New)
Jim Simons 504,107 sh (New)
Steven Cohen 453,700 sh (+256.40%)
Mario Gabelli 217,519 sh (unchged)
Ken Fisher 2,414,922 sh (-3.55%)
Eaton Vance Worldwide Health Sciences Fund 920,760 sh (-8.77%)
» More
» Details

Insider Trades

Latest Guru Trades with WMGI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 339113    SIC: 3842
Compare:OTCPK:AMBFF, NAS:LIVN, NYSE:GMED, NYSE:PEN, OTCPK:SHWGY, NAS:ZLTQ, NAS:IART, NYSE:NVRO, NAS:NUVA, OTCPK:NHNKY, OTCPK:EKTAY, OTCPK:FSPKF, NAS:INGN, OTCPK:IOBCF, OTCPK:GGNDF, NAS:CYNO, NAS:MDXG, NAS:CNMD, NAS:MASI, NYSE:ITGR » details
Traded in other countries:T98.Germany,
Headquarter Location:Netherlands
Wright Medical Group NV is a medical device company that designs, manufactures, markets & sells extremities and biologics products in USA & internationally. It offers joint implants & bone fusion & fixation devices for shoulder, elbow, wrist, and hand.

Wright Medical Group develops medical devices and products in five categories: lower extremities, upper extremities, biologics, large joints, and sport medicine, and other. Products for lower extremities include joint implants and bone fixation devices for the foot and ankle, whereas products for upper extremities include implants and devices for the shoulder, elbow, wrist, and hand. The biologics business sells products used to treat damaged or diseased bone, tendons, and soft tissues or to stimulate bone growth. The large joints business sells hip and knee replacement implants. The firm's sports medicine products are used to mechanically repair tissue injuries. Wright Medical Group generates the majority of its revenue in the United States.

Guru Investment Theses on Wright Medical Group NV

Keeley Funds Comments on Wright Medical Group - Apr 27, 2017

Wright Medical Group (NASDAQ:WMGI) is a global medical device company focused on extremities and biologics. The company completed a merger of equals with Tornier NV in late 2015 becoming the worldwide leader in providing surgical solutions for upper extremities (shoulder, elbow, wrist and hands), lower extremities (foot and ankle) and biologics (bone graft stimulators) - three of the fastest growing segments in orthopedics. Both companies had been investing heavily for growth resulting in low, short-term profitability, but under new CEO Robert Palmisano, the combined company has substantial scale opportunities and would be a beneficiary of the aging, but much more active baby boom generation. The company has exceeded analysts’ estimates for the past four quarters post the deal closing and EBITDA margins have increased from -5.5% in 4Q15 to 11.7% in 4Q16, on its way towards our 20% margin target by 2019. In addition, a recent Financial Times article reported on speculation that a larger orthopedic company may be looking to acquire Wright. Given the consolidation in the orthopedic market and CEO Palmisano’s history of selling his prior companies, we would not be surprised if a strategic player recognizes Wright’s intrinsic value sooner than expected.



From the Keeley Small Cap Value Fund first quarter 2017 commentary.



Check out John Keeley latest stock trades

Keeley Asset Management Comments on Wright Medical Group - Oct 21, 2016

One of the Fund’s main drivers this quarter was Wright Medical Group (NASDAQ:WMGI), which gained nearly 40% and contributed 141 basis points in performance. The company provides surgical solutions for the foot and ankle market and its products include joint implants for hip and knee replacements. The company reported a strong second quarter and raised guidance, proving the benefit of the Tornier acquisition.



From Keeley All Cap Value Fund third-quarter 2016 commentary.



Check out Keeley Asset Management Corp latest stock trades

John Keeley Comments on Wright Medical Group - Apr 26, 2016

Health Care proved to be challenging this quarter and our leading detractors all came from this sector. Despite a positive quarter and the completion of a recent European based acquisition, Wright Medical Group (NASDAQ:WMGI) stock was pressured on fears of potential litigation involving metal to metal hip implants, which could exceed the company’s liability insurance. Other orthopedic companies have suffered from similar legal disputes involving alleged, early device failure in recent years. A judgement was recently handed down on its first case with 80% less in damages awarded than had been initially estimated. Regardless of what appears to be a favorable outcome, WMGI plans to appeal the case and ultimately hopes to certify and settle the class of claims well within its liability insurance limits. We believe WMGI will ultimately prevail on this issue and the stock remains attractive.



From Keeley All Cap Value Fund first quarter 2016 commentary.



Check out John Keeley latest stock trades

Top Ranked Articles about Wright Medical Group NV

Wright Medical Group N.V. to Present at UBS Global Healthcare Conference
Keeley Funds Comments on Wright Medical Group Guru stock highlight
Wright Medical Group (NASDAQ:WMGI) is a global medical device company focused on extremities and biologics. The company completed a merger of equals with Tornier NV in late 2015 becoming the worldwide leader in providing surgical solutions for upper extremities (shoulder, elbow, wrist and hands), lower extremities (foot and ankle) and biologics (bone graft stimulators) - three of the fastest growing segments in orthopedics. Both companies had been investing heavily for growth resulting in low, short-term profitability, but under new CEO Robert Palmisano, the combined company has substantial scale opportunities and would be a beneficiary of the aging, but much more active baby boom generation. The company has exceeded analysts’ estimates for the past four quarters post the deal closing and EBITDA margins have increased from -5.5% in 4Q15 to 11.7% in 4Q16, on its way towards our 20% margin target by 2019. In addition, a recent Financial Times article reported on speculation that a larger orthopedic company may be looking to acquire Wright. Given the consolidation in the orthopedic market and CEO Palmisano’s history Read more...
Wright Medical Group N.V. to Host First Quarter 2017 Earnings Conference Call
Wright Medical Group N.V. to Present at Needham Healthcare Conference

Wednesday, April 5, 2017 at 2:20 p.m. Eastern Time 

AMSTERDAM, The Netherlands, March 24, 2017 (GLOBE NEWSWIRE) -- Wright Medical Group N.V. (NASDAQ:WMGI) announced today that it will present at the Needham Healthcare Conference on Wednesday, April 5, 2017, at the Westin NY Grand Central Hotel in New York, New York.  Lance Berry, chief financial officer, will present at 2:20 p.m. Eastern Time.  
A live audio webcast of the conference presentation, along with the accompanying presentation materials, will be available on Wright’s corporate website at www.wright.com, under the “Investor Relations” link.  The audio webcast and accompanying presentation materials will be archived on this site under the “Investor Presentations” link following the conference. Internet Posting of Information Wright routinely posts information that may be important to investors in the “Investor Relations” section of its website at www.wright.com.  The company encourages investors and potential investors to consult the Wright website regularly for important information about Wright. About Wright Medical Group N.V. Wright Medical Group N.V. is a global medical device company focused on extremities and biologics products.  The company is committed to delivering innovative, value-added solutions improving quality of life for patients worldwide and is a recognized leader of surgical solutions for the upper extremity (shoulder, elbow, wrist and hand), lower extremity (foot and ankle) and biologics markets, three of the fastest growing segments in orthopedics.  For more information about Wright, visit www.wright.com.
Investors & Media:

Julie D. Tracy
Sr. Vice President, Chief Communications Officer
Wright Medical Group N.V.
(901) 290-5817
[email protected]


Read more...
Keeley Asset Management Comments on Wright Medical Group Guru stock highlight
One of the Fund’s main drivers this quarter was Wright Medical Group (NASDAQ:WMGI), which gained nearly 40% and contributed 141 basis points in performance. The company provides surgical solutions for the foot and ankle market and its products include joint implants for hip and knee replacements. The company reported a strong second quarter and raised guidance, proving the benefit of the Tornier acquisition. Read more...

Ratios

vs
industry
vs
history
PB Ratio 4.32
WMGI's PB Ratio is ranked lower than
68% of the 298 Companies
in the Global Medical Devices industry.

( Industry Median: 3.11 vs. WMGI: 4.32 )
Ranked among companies with meaningful PB Ratio only.
WMGI' s PB Ratio Range Over the Past 10 Years
Min: 1.47  Med: 2.09 Max: 4.95
Current: 4.32
1.47
4.95
PS Ratio 4.01
WMGI's PS Ratio is ranked lower than
65% of the 296 Companies
in the Global Medical Devices industry.

( Industry Median: 3.20 vs. WMGI: 4.01 )
Ranked among companies with meaningful PS Ratio only.
WMGI' s PS Ratio Range Over the Past 10 Years
Min: 2.22  Med: 3.45 Max: 5.13
Current: 4.01
2.22
5.13
Price-to-Operating-Cash-Flow 84.88
WMGI's Price-to-Operating-Cash-Flow is ranked lower than
94% of the 140 Companies
in the Global Medical Devices industry.

( Industry Median: 20.26 vs. WMGI: 84.88 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
WMGI' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 26.97  Med: 40.52 Max: 167.07
Current: 84.88
26.97
167.07
EV-to-EBIT -33.58
WMGI's EV-to-EBIT is ranked lower than
99.99% of the 275 Companies
in the Global Medical Devices industry.

( Industry Median: 24.54 vs. WMGI: -33.58 )
Ranked among companies with meaningful EV-to-EBIT only.
WMGI' s EV-to-EBIT Range Over the Past 10 Years
Min: -220.5  Med: -16.3 Max: -3.1
Current: -33.58
-220.5
-3.1
EV-to-EBITDA -229.49
WMGI's EV-to-EBITDA is ranked lower than
99.99% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 19.31 vs. WMGI: -229.49 )
Ranked among companies with meaningful EV-to-EBITDA only.
WMGI' s EV-to-EBITDA Range Over the Past 10 Years
Min: -304.6  Med: -17.1 Max: 640.7
Current: -229.49
-304.6
640.7
Current Ratio 0.95
WMGI's Current Ratio is ranked lower than
74% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: 2.38 vs. WMGI: 0.95 )
Ranked among companies with meaningful Current Ratio only.
WMGI' s Current Ratio Range Over the Past 10 Years
Min: 0.95  Med: 2.62 Max: 3.29
Current: 0.95
0.95
3.29
Quick Ratio 0.80
WMGI's Quick Ratio is ranked lower than
67% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: 1.79 vs. WMGI: 0.80 )
Ranked among companies with meaningful Quick Ratio only.
WMGI' s Quick Ratio Range Over the Past 10 Years
Min: 0.8  Med: 1.56 Max: 1.99
Current: 0.8
0.8
1.99
Days Inventory 348.62
WMGI's Days Inventory is ranked lower than
90% of the 289 Companies
in the Global Medical Devices industry.

( Industry Median: 130.04 vs. WMGI: 348.62 )
Ranked among companies with meaningful Days Inventory only.
WMGI' s Days Inventory Range Over the Past 10 Years
Min: 342.93  Med: 428.02 Max: 530.83
Current: 348.62
342.93
530.83
Days Sales Outstanding 62.38
WMGI's Days Sales Outstanding is ranked higher than
51% of the 272 Companies
in the Global Medical Devices industry.

( Industry Median: 68.94 vs. WMGI: 62.38 )
Ranked among companies with meaningful Days Sales Outstanding only.
WMGI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 62.38  Med: 71.27 Max: 118.01
Current: 62.38
62.38
118.01
Days Payable 71.97
WMGI's Days Payable is ranked higher than
51% of the 259 Companies
in the Global Medical Devices industry.

( Industry Median: 59.71 vs. WMGI: 71.97 )
Ranked among companies with meaningful Days Payable only.
WMGI' s Days Payable Range Over the Past 10 Years
Min: 51.36  Med: 83.39 Max: 156.08
Current: 71.97
51.36
156.08

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -28.70
WMGI's 3-Year Average Share Buyback Ratio is ranked lower than
85% of the 218 Companies
in the Global Medical Devices industry.

( Industry Median: -3.90 vs. WMGI: -28.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
WMGI' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -35  Med: -20 Max: -7.6
Current: -28.7
-35
-7.6

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 1.17
WMGI's Price-to-Median-PS-Value is ranked lower than
74% of the 242 Companies
in the Global Medical Devices industry.

( Industry Median: 1.03 vs. WMGI: 1.17 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
WMGI' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0  Med: 1.04 Max: 1.41
Current: 1.17
0
1.41
Earnings Yield (Greenblatt) % -2.97
WMGI's Earnings Yield (Greenblatt) % is ranked lower than
67% of the 432 Companies
in the Global Medical Devices industry.

( Industry Median: 2.17 vs. WMGI: -2.97 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
WMGI' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -3.54  Med: 0 Max: 371.59
Current: -2.97
-3.54
371.59

More Statistics

Revenue (TTM) (Mil) $698.3
EPS (TTM) $ -4.30
Beta1.21
Short Percentage of Float14.56%
52-Week Range $15.85 - 31.53
Shares Outstanding (Mil)104.30

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 759 859 997
EPS ($) -0.32 0.01 0.15
EPS without NRI ($) -0.32 0.01 0.15
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for WMGI

Headlines

Articles On GuruFocus.com
Eaton Vance Worldwide Health Sciences Fund 1st Quarter Investment Report May 02 2017 
Wright Medical Group N.V. to Present at UBS Global Healthcare Conference May 02 2017 
Keeley Funds Comments on Wright Medical Group Apr 27 2017 
KEELEY Small Cap Value Fund 1st Quarter Commentary Apr 27 2017 
Wright Medical Group N.V. to Host First Quarter 2017 Earnings Conference Call Apr 12 2017 
Wright Medical Group N.V. to Present at Needham Healthcare Conference Mar 24 2017 
Keeley Asset Management Comments on Wright Medical Group Oct 21 2016 
KEELEY All Cap Value Fund 3rd Quarter Commentary Oct 21 2016 
Sam Isaly Swaps 3 Health Care Stocks in Second Quarter Jul 29 2016 
John Keeley Comments on Wright Medical Group Apr 26 2016 

More From Other Websites
Wright Medical Group N.V. to Present at Jefferies Healthcare Conference May 18 2017
ETFs with exposure to Wright Medical Group NV : May 11, 2017 May 11 2017
Wright Medical Group NV :WMGI-US: Earnings Analysis: Q1, 2017 By the Numbers : May 9, 2017 May 09 2017
Wright Medical Group NV – Value Analysis (NASDAQ:WMGI) : May 8, 2017 May 08 2017
Edited Transcript of WMGI earnings conference call or presentation 3-May-17 8:30pm GMT May 08 2017
Wright Medical Group NV breached its 50 day moving average in a Bearish Manner : WMGI-US : May 5,... May 05 2017
Wright Medical (WMGI) Posts Wider-than-Expected Loss in Q1 May 05 2017
Wright Medical reports net loss, optimism for year ahead May 04 2017
Wright Medical reports 1Q loss May 03 2017
Wright Medical Group N.V. Reports 2017 First Quarter Financial Results May 03 2017
Investor Network: Wright Medical Group NV to Host Earnings Call May 03 2017
Wright Medical Group N.V. to Present at UBS Global Healthcare Conference May 02 2017
Wright Medical Group N.V. to Host First Quarter 2017 Earnings Conference Call Apr 12 2017
Why Is Wright Medical (WMGI) Up 8.7% Since the Last Earnings Report? Mar 24 2017
Wright Medical Group N.V. to Present at Needham Healthcare Conference Mar 24 2017
Wright Medical Group NV :WMGI-US: Earnings Analysis: 2016 By the Numbers : February 23, 2017 Feb 23 2017
Wright Pops To Nearly 6-Year High On Strong Q4 Results, 2017 Outlook Feb 22 2017
Wright Medical (WMGI) Posts Narrower-than-Expected Q4 Loss Feb 22 2017
Edited Transcript of WMGI earnings conference call or presentation 21-Feb-17 9:30pm GMT Feb 22 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat